Linda F. Powers as CYDY's new CEO is something to
Post# of 153854
(Total Views: 859)
Posted On: 05/06/2022 4:01:06 PM
Linda F. Powers as CYDY's new CEO is something to consider.
WHY?
====
As per Ritztheinvestor and USS JOHNSTON posts Ms. Powers checks everyones box. At least read check box [11] which is my favorite point here.
WHO IS MS. POWERS?
====================
Ms. Powers, as current CEO of NWBO one can imagine on 5/10 Phase 3 reveal we learn DCVax®-L for Glioblastoma will have same results of 2 1/2 times longer survival than typical 14+ months survival in the Phase 2 trial. Some patients have a 10 year survival. NEGATIVE: No mention of side effects, no mention that there are little to no side effects <== that is not transparent
WHAT IS GLIOBLASTOMA?
======================
Glioblastoma I understand although rare, is the most prevelant form of brain cancer and, although rare, for unknown reasons is becoming more common.
Here are the boxes MS. POWERS checks off
===================================
[01] woman CEO - may have better credibility under FDA eyes
[02] B.A. Princeton, magna cum laude
[03] J.D. Harvard Law, magna cum laude
[04] ASSUMPTION: will get FDA approval of DCVax®-L for Glioblastoma
[05] We get a partnership without selling out to big pharma (not as great a dilution of our investment)
[06] We get NWBO stock that will still be 50% Leronlimab stock
[07] Leronlimab will get closer to 100% of NWBO's value because of the many indications of much much more prevalant diseases
[08] taught for more than six years at the National Institutes of Health, on medical product development and commercialization, and at Georgetown Law School as an adjunct professor. -- may be able to get funding for multiple LL trials from NIH
[09] previously served as a Managing Director of Toucan Capital Fund II, an investment fund focused on regenerative medicine and immune therapies, from 2001 to 2010
[10] has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing.
[11] My thinking: upon DCVax®-L FDA aproval -- BOOM! -- Ms. Powers has new credibility and ability to direct CYDY in a manner that focuses on results -- because she has an up to date proven track record at that point <== this is valuable to CYDY shareholders
[12]
[13]
[14]
CONCLUDING COMMENTS
=======================
fill in[12], [13], [14] check boxes, please why don't you.
My only goal here is for CYDY decision makers to consider Ms. Powers
"Side effects reported from early trials are mostly mild"
says https://clinicaltrials.gov/ct2/show/NCT00045968
?? mostly ?? SO we need to ask what are the severe although uncommon side effects? Death or what?
WHY?
====
As per Ritztheinvestor and USS JOHNSTON posts Ms. Powers checks everyones box. At least read check box [11] which is my favorite point here.
WHO IS MS. POWERS?
====================
Ms. Powers, as current CEO of NWBO one can imagine on 5/10 Phase 3 reveal we learn DCVax®-L for Glioblastoma will have same results of 2 1/2 times longer survival than typical 14+ months survival in the Phase 2 trial. Some patients have a 10 year survival. NEGATIVE: No mention of side effects, no mention that there are little to no side effects <== that is not transparent
WHAT IS GLIOBLASTOMA?
======================
Glioblastoma I understand although rare, is the most prevelant form of brain cancer and, although rare, for unknown reasons is becoming more common.
Here are the boxes MS. POWERS checks off
===================================
[01] woman CEO - may have better credibility under FDA eyes
[02] B.A. Princeton, magna cum laude
[03] J.D. Harvard Law, magna cum laude
[04] ASSUMPTION: will get FDA approval of DCVax®-L for Glioblastoma
[05] We get a partnership without selling out to big pharma (not as great a dilution of our investment)
[06] We get NWBO stock that will still be 50% Leronlimab stock
[07] Leronlimab will get closer to 100% of NWBO's value because of the many indications of much much more prevalant diseases
[08] taught for more than six years at the National Institutes of Health, on medical product development and commercialization, and at Georgetown Law School as an adjunct professor. -- may be able to get funding for multiple LL trials from NIH
[09] previously served as a Managing Director of Toucan Capital Fund II, an investment fund focused on regenerative medicine and immune therapies, from 2001 to 2010
[10] has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing.
[11] My thinking: upon DCVax®-L FDA aproval -- BOOM! -- Ms. Powers has new credibility and ability to direct CYDY in a manner that focuses on results -- because she has an up to date proven track record at that point <== this is valuable to CYDY shareholders
[12]
[13]
[14]
CONCLUDING COMMENTS
=======================
fill in[12], [13], [14] check boxes, please why don't you.
My only goal here is for CYDY decision makers to consider Ms. Powers
"Side effects reported from early trials are mostly mild"
says https://clinicaltrials.gov/ct2/show/NCT00045968
?? mostly ?? SO we need to ask what are the severe although uncommon side effects? Death or what?
(1)
(0)